Valneva SE

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

11 окт 2023 11:45:00 Источник Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: September 30, 2023

05 окт 2023 02:30:00 Источник Nasdaq GlobeNewswire

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million

25 сен 2023 01:00:00 Источник Nasdaq GlobeNewswire

Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates

21 сен 2023 01:00:00 Источник Nasdaq GlobeNewswire

Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate

07 сен 2023 01:00:00 Источник Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: August 31, 2023

06 сен 2023 02:30:00 Источник Nasdaq GlobeNewswire

Valneva to Participate in Investor Conferences in the United States and Europe in September 2023

31 авг 2023 13:00:00 Источник Nasdaq GlobeNewswire

Health Canada Accepts Valneva’s Chikungunya Vaccine License Application for Review

29 авг 2023 01:00:00 Источник Nasdaq GlobeNewswire

Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate

28 авг 2023 01:00:00 Источник Nasdaq GlobeNewswire

Valneva Announces Extension of Existing Loan Agreement

17 авг 2023 01:00:00 Источник Nasdaq GlobeNewswire

Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate

14 авг 2023 01:00:00 Источник Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights - July 31, 2023

03 авг 2023 02:30:00 Источник Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: June 30, 2023

05 июл 2023 02:30:00 Источник Nasdaq GlobeNewswire

Valneva Supervisory Board Recommends Transition from a Two-Tier Governance Model to a Board of Directors

22 июн 2023 01:00:00 Источник Nasdaq GlobeNewswire

  Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizer’s Former Vaccine R&D Head to its Supervisory Board

21 июн 2023 12:15:00 Источник Nasdaq GlobeNewswire

Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet

13 июн 2023 01:00:00 Источник Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: May 31, 2023

07 июн 2023 02:00:00 Источник Nasdaq GlobeNewswire

Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

31 май 2023 01:15:00 Источник Nasdaq GlobeNewswire

Valneva Announces the Availability of Documentation for its Shareholder Meeting

31 май 2023 01:00:00 Источник Nasdaq GlobeNewswire

Valneva Files for Chikungunya Vaccine Authorization with Health Canada

30 май 2023 01:00:00 Источник Nasdaq GlobeNewswire